Abstract
Brain tumor remains one of the most serious threats to human beings. Different from peripheral tumors, drug delivery to brain tumor is largely restricted by the blood brain barrier (BBB). To fully conquer this barrier and specifically deliver drugs to brain tumor, dual targeting delivery systems were explored, which are functionalized with two active targeting ligands: one to the BBB and the other to the brain tumor. The development of dual targeting delivery system is still in its early stage, and attentions need to be paid to issues and concerns that remain unresolved in future studies.
Similar content being viewed by others
References
Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF (2011) Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 13:e17
Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF (2013) Function of the blood–brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos 41:33–39
Avvakumova S, Colombo M, Tortora P, Prosperi D (2014) Biotechnological approaches toward nanoparticle biofunctionalization. Trends Biotechnol 32:11–20
Banks WA, Tschop M, Robinson SM, Heiman ML (2002) Extent and direction of ghrelin transport across the blood–brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther 302:822–827
Barczyk M, Carracedo S, Gullberg D (2010) Integrins. Cell Tissue Res 339:269–280
Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO (2009) Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86:151–164
Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104:29–45
Bien-Ly N, Yu YJ, Bumbaca D, Elstrott J, Boswell CA, Zhang Y, et al. (2014) Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J Exp Med 211:233–244
Bruun J, Larsen TB, Jolck RI, Eliasen R, Holm R, Gjetting T, et al. (2015) Investigation of enzyme-sensitive lipid nanoparticles for delivery of siRNAto blood–brain barrier and glioma cells. Int J Nanomedicine 10:5995–6008
Butt AM, Jones HC, Abbott NJ (1990) Electrical resistance across the blood–brain barrier in anaesthetized rats: a developmental study. J Physiol 429:47–62
Byeon HJ, Thao LQ, Lee S, Min SY, Lee ES, Shin BS, et al. (2016) Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors. J Control Release 225:301–313
Chen YC, Chiang CF, Chen LF, Liang PC, Hsieh WY, Lin WL (2014) Polymersomes conjugated with des-octanoyl ghrelin and folate as a BBB-penetrating cancer cell-targeting delivery system. Biomaterials 35:4066–4081
Chen J, Cun X, Ruan S, Wang Y, Zhang Y, He Q, et al. (2015a) Glioma cell-targeting doxorubicin delivery and redox-responsive release using angiopep-2 decorated carbonaceous nanodots. RSC Adv 5:57045–57049
Chen W, Zheng R, Zeng H, Zhang S, He J (2015b) Annual report on status of cancer in China, 2011. Chin J Cancer Res 27:2–12
Choi CH, Alabi CA, Webster P, Davis ME (2010) Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A 107:1235–1240
Clark AJ, Davis ME (2015) Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core. Proc Natl Acad Sci U S A 112:12486–12491
Cruz LJ, Tacken PJ, Fokkink R, Figdor CG (2011) The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials 32:6791–6803
Demeule M, Regina A, Che C, Poirier J, Nguyen T, Gabathuler R, et al. (2008) Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 324:1064–1072
Ding HM, Ma YQ (2012) Role of physicochemical properties of coating ligands in receptor-mediated endocytosis of nanoparticles. Biomaterials 33:5798–5802
Dixit S, Miller K, Zhu Y, McKinnon E, Novak T, Kenney ME, et al. (2015) Dual receptor-targeted theranostic nanoparticles for localized delivery and activation of photodynamic therapy drug in glioblastomas. Mol Pharm 12:3250–3260
Du J, Lu WL, Ying X, Liu Y, Du P, Tian W, et al. (2009) Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood–brain barrier and survival of brain tumor-bearing animals. Mol Pharm 6:905–917
Du D, Chang N, Sun S, Li M, Yu H, Liu M, et al. (2014) The role of glucose transporters in the distribution of p-aminophenyl-alpha-d-mannopyranoside modified liposomes within mice brain. J Control Release 182:99–110
Farkas MH, Weisgraber KH, Shepherd VL, Linton MF, Fazio S, Swift LL (2004) The recycling of apolipoprotein E and its amino-terminal 22 kDa fragment: evidence for multiple redundant pathways. J Lipid Res 45:1546–1554
Feng X, Yao J, Gao X, Jing Y, Kang T, Jiang D, et al. (2015) Multi-targeting peptide-functionalized nanoparticles recognized vasculogenic mimicry, tumor neovasculature, and glioma cells for enhanced anti-glioma therapy. ACS Appl Mater Interfaces 7:27885–27899
Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, Muzik H, et al. (1999) Gelatinase-a (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 79:1828–1835
Gao K, Jiang X (2006) Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int J Pharm 310:213–219
Gao H, He Q (2014) The interaction of nanoparticles with plasma proteins and the consequent influence on nanoparticles behavior. Expert Opin Drug Deliv 11:409–420
Gao H, Jiang X (2015) Brain delivery using nanotechnology. In: Di Li and Edward HK (ed) Blood-brain barrier in drug discovery: optimizing brain exposure of CNS drugs and minimizing brain side effects, John Wiley & Sons, New York, pp 521–534
Gao H, Pan S, Yang Z, Cao S, Chen C, Jiang X, et al. (2011) A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. Biomaterials 32:8669–8675
Gao H, Pang Z, Pan S, Cao S, Yang Z, Chen C, et al. (2012a) Anti-glioma effect and safety of docetaxel-loaded nanoemulsion. Arch Pharm Res 35:333–341
Gao H, Qian J, Cao S, Yang Z, Pang Z, Pan S, et al. (2012b) Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 33:5115–5123
Gao H, Yang Z, Zhang S, Cao S, Shen S, Pang Z, et al. (2013a) Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Report 3:2534
Gao H, Pang Z, Jiang X (2013b) Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Pharm Res 30:2485–2498
Gao H, Yang Z, Cao S, Xiong Y, Zhang S, Pang Z, et al. (2014a) Tumor cells and neovasculature dual targeting delivery for glioblastoma treatment. Biomaterials 35:2374–2382
Gao H, Wang Y, Chen C, Chen J, We Y, Cao S, et al. (2014b) Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug. Int J Pharm 461:478–488
Gao H, Xiong Y, Zhang S, Yang Z, Cao S, Jiang X (2014c) RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration. Mol Pharm 11:1042–1052
Gao H, Yang Z, Zhang S, Pang Z, Liu Q, Jiang X (2014d) Study and evaluation of mechanisms of dual targeting drug delivery system with tumor microenvironment assays compared with normal assays. Acta Biomater 10:858–867
Gao H, Zhang S, Cao S, Yang Z, Pang Z, Jiang X (2014e) Angiopep-2 and activatable cell-penetrating peptide dual-functionalized nanoparticles for systemic glioma-targeting delivery. Mol Pharm 11:2755–2763
Gao H, Yang Z, Zhang S, Pang Z, Jiang X (2014f) Internalization and subcellular fate of aptamer and peptide dual-functioned nanoparticles. J Drug Target 22:450–459
Gorin F, Harley W, Schnier J, Lyeth B, Jue T (2004) Perinecrotic glioma proliferation and metabolic profile within an intracerebral tumor xenograft. Acta Neuropathol 107:235–244
Guo J, Gao X, Su L, Xia H, Gu G, Pang Z, et al. (2011) Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 32:8010–8020
Hu G, Chun X, Wang Y, He Q, Gao H (2015) Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment. Oncotarget 6:41258–41274
Huang WC, Burnouf PA, Su YC, Chen BM, Chuang KH, Lee CW, et al. (2016) Engineering chimeric receptors to investigate the size- and rigidity-dependent interaction of PEGylated nanoparticles with cells. ACS Nano
Ito S, Ohtsuki S, Terasaki T (2006) Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood–brain barrier. Neurosci Res 56:246–252
Jiang X, Xin H, Ren Q, Gu J, Zhu L, Du F″ ", et al. (2014) Nanoparticles of 2-deoxy-D-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials 35: 518–529.
Ke W, Shao K, Huang R, Han L, Liu Y, Li J, et al. (2009) Gene delivery targeted to the brain using an angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 30:6976–6985
Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H (2013) The effect of liposomal size on the targeted delivery of doxorubicin to integrin alphavbeta3-expressing tumor endothelial cells. Biomaterials 34:5617–5627
Kolate A, Baradia D, Patil S, Vhora I, Kore G, Misra A (2014) PEG - a versatile conjugating ligand for drugs and drug delivery systems. J Control Release 192C:67–81
Kolhar P, Anselmo AC, Gupta V, Pant K, Prabhakarpandian B, Ruoslahti E, et al. (2013) Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc Natl Acad Sci U S A 110:10753–10758
Larson TA, Joshi PP, Sokolov K (2012) Preventing protein adsorption and macrophage uptake of gold nanoparticles via a hydrophobic shield. ACS Nano 6:9182–9190
Lee KH, Ytreberg FM (2012) Effect of gold nanoparticle conjugation on peptide dynamics and structure. Entropy 14:630–641
Li H, Qian ZM (2002) Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev 22:225–250
Li J, Feng L, Fan L, Zha Y, Guo L, Zhang Q, et al. (2011) Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 32:4943–4950
Li XY, Zhao Y, Sun MG, Shi JF, Ju RJ, Zhang CX, et al. (2014) Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma. Biomaterials 35:5591–5604
Liu Y, Ran R, Chen J, Kuang Q, Tang J, Mei L, et al. (2014) Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting. Biomaterials 35:4835–4847
Lu W, Wan J, She Z, Jiang X (2007) Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J Control Release 118:38–53
Mahmoudi M, Sheibani S, Milani AS, Rezaee F, Gauberti M, Dinarvand R, et al. (2015) Crucial role of the protein corona for the specific targeting of nanoparticles. Nanomedicine (London) 10:215–226
Maletinska L, Blakely EA, Bjornstad KA, Deen DF, Knoff LJ, Forte TM (2000) Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res 60:2300–2303
Mazzucchelli S, Colombo M, Verderio P, Rozek E, Andreata F, Galbiati E, et al. (2013) Orientation-controlled conjugation of Haloalkane dehalogenase fused homing peptides to multifunctional nanoparticles for the specific recognition of cancer cells. Angew Chem Int Ed 52:3121–3125
Mei L, Zhang Q, Yang Y, He Q, Gao H (2014) Angiopep-2 and activatable cell penetrating peptide dual modified nanoparticles for enhanced tumor targeting and penetrating. Int J Pharm 474:95–102
Mintz A, Gibo DM, Slagle-Webb B, Christensen ND, Debinski W (2002) IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia 4:388–399
Mishra V, Kesharwani P. (2016) Dendrimer technologies for brain tumor. Drug Discov Today 21:766–78
Ni D, Zhang J, Bu W, Xing H, Han F, Xiao Q, et al. (2014) Dual-targeting upconversion nanoprobes across the blood–brain barrier for magnetic resonance/fluorescence imaging of intracranial glioblastoma. ACS Nano 8:1231–1242
Owens R, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307:93–102
Pang Z, Lu W, Gao H, Hu K, Chen J, Zhang C, et al. (2008) Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release 128:120–127
Pardridge WM (2002) Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 1:131–139
Pardridge WM (2007) Drug targeting to the brain. Pharm Res 24:1733–1744
Peiris PM, Abramowski A, Mcginnity J, Doolittle E, Toy R, Gopalakrishnan R, et al. (2015) Treatment of invasive brain tumors using a chain-like nanoparticle. Cancer Res 75:1356–1365
Popovic Z, Liu W, Chauhan VP, Lee J, Wong C, Greytak AB, et al. (2010) A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Eng 49:8649–8652
Qosa H, Miller DS, Pasinelli P, Trotti D (2015) Regulation of ABC efflux transporters at blood–brain barrier in health and neurological disorders. Brain Res 1628:298–316
Ruan S, Zhang L, Chen J, Cao T, Yang Y, Liu Y, et al. (2015a) Targeting delivery and deep penetration using multistage nanoparticles for triple-negative breast cancer. RSC Adv 5:64303–64317
Ruan S, Yuan M, Zhang L, Hu G, Chen J, Cun X, et al. (2015b) Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles. Biomaterials 37:425–435
Ruan S, Cao X, Cun X, Hu G, Zhou Y, Zhang Y, et al. (2015c) Matrix metalloproteinase-sensitive size-shrinkable nanoparticles for deep tumor penetration and pH triggered doxorubicin release. Biomaterials 60:100–110
Ruan S, He Q, Gao H (2015d) Matrix metalloproteinase triggered size-shrinkable gelatin-gold fabricated nanoparticles for tumor microenvironment sensitive penetration and diagnosis of glioma. Nanoscale 7:9487–9496
Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, Hristov DR, et al. (2013) Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 8:137–143
Sarin H, Kanevsky AS, Wu H, Sousa AA, Wilson CM, Aronova MA, et al. (2009) Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J Transl Med 7:51
Schottelius M, Laufer B, Kessler H, Wester HJ (2009) Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res 42:969–980
Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, et al. (2005) Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436:568–572
Shilo M, Sharon A, Baranes K, Motiei M, Lellouche JP, Popovtzer R (2015) The effect of nanoparticle size on the probability to cross the blood–brain barrier: an in-vitro endothelial cell model. J Nanomater 13:19
Sun X, Pang Z, Ye H, Qiu B, Guo L, Li J, et al. (2012) Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome. Biomaterials 33:916–924
Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, et al. (2012) Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res 29:770–781
Tomitaka A, Arami H, Gandhi S, Krishnan KM (2015) Lactoferrin conjugated iron oxide nanoparticles for targeting brain glioma cells in magnetic particle imaging. Nanoscale 7:16890–16898
Valencia PM, Hanewich-Hollatz MH, Gao W, Karim F, Langer R, Karnik R, et al. (2011) Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials 32:6226–6233
van der Meel R, Vehmeijer LJ, Kok RJ, Storm G, van Gaal EV (2013) Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev 65:1284–1298
Weissig V, Pettinger TK, Murdock N (2014) Nanopharmaceuticals (part 1): products on the market. Int J Nanomedicine 9:4357–4373
Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski V, et al. (1992) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52:3396–3401
Wiley DT, Webster P, Gale A, Davis ME (2013) Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci U S A 110:8662–8667
Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W, et al. (2011) Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A 108:2426–2431
Wong HL, Wu XY, Bendayan R (2012) Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 64:686–700
Xu F, Reiser M, Yu X, Gummuluru S, Wetzler RBM (2016) Lipid-mediated targeting with membrane-wrapped nanoparticles in the presence of corona formation. ACS Nano 2016(10):1189–1200
Yan H, Wang L, Wang J, Weng X, Lei H, Wang X, et al. (2012) Two-order targeted brain tumor imaging by using an optical/paramagnetic Nanoprobe across the blood brain barrier. ACS Nano 6:410–420
Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, et al. (2011) Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 3: 44r-84r.
Zhan C, Lu W. (2012) The blood-brain/tumor barriers: challenges and chances for malignant gliomas targeted drug delivery. Curr Pharm Biotechnol 13:2380–2387
Zhang J, Chen N, Wang H, Gu W, Liu K, Ai P, et al. (2016a) Dual-targeting superparamagnetic iron oxide nanoprobes with high and low target density for brain glioma imaging. J Colloid Interface Sci 469:86–92
Zhang T, Li W, Meng G, Wang P, Liao W (2016b) Strategies for transporting nanoparticles across the blood–brain barrier. Biomater Sci 4:219–229
Acknowledgments
This work was supported by the National Natural Science Foundation of China (81402866, 31571016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Gao, H. Perspectives on Dual Targeting Delivery Systems for Brain Tumors. J Neuroimmune Pharmacol 12, 6–16 (2017). https://doi.org/10.1007/s11481-016-9687-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11481-016-9687-4